Myriad Genetics Inc (MYGN) stock
MYGNNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 8/3070% below fair value
$5.54−0.03 (-0.54%)
Close on Nov 17, 2026Market cap $529.90MP/E –Yield –
Myriad Genetics EV/EBITDA
EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.
Myriad Genetics's EV/EBITDA was 28.3× on Apr 30, 2020, against 23.4× a year earlier. Over the last 5 years it ranged from 6.7× to 36.6×, with a median of 15.8×.
EV/EBITDA at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2020 | Apr 30, 2020 | 28.3× | −7.8 |
| 2019 | Dec 31, 2019 | 36.1× | +13.1 |
| 2018 | Dec 31, 2018 | 23.0× | +10.4 |
| 2017 | Dec 29, 2017 | 12.5× | +4.4 |
| 2016 | Dec 30, 2016 | 8.1× | −7.9 |
| 2015 | Dec 31, 2015 | 16.1× | +6.2 |
| 2014 | Dec 31, 2014 | 9.9× | +5.3 |
| 2013 | Dec 31, 2013 | 4.6× | −4.9 |
| 2012 | Dec 31, 2012 | 9.5× | +1.2 |
| 2011 | Dec 30, 2011 | 8.3× | −3.1 |
| 2010 | Dec 31, 2010 | 11.4× | −7.1 |
| 2009 | Dec 31, 2009 | 18.5× | – |
See a number that looks wrong?